Agios Pharmaceuticals IncNASDAQ:AGIO
- LAST PRICE29.4300
- TODAY'S CHANGE (%)0.4000 (1.3779%)
- Bid / Lots11.7800/ 2
- Ask / Lots30.4000/ 1
- Open / Previous Close29.1000 / 29.0300
- Day Range
- 52 Week Range
- Volume549,540
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | AGIO |
|---|---|---|
| 09:32 ET | 2249 | 29.065 |
| 09:34 ET | 100 | 29.35 |
| 09:38 ET | 356 | 29.42 |
| 09:39 ET | 800 | 29.41 |
| 09:41 ET | 300 | 29.49 |
| 09:43 ET | 327 | 29.36 |
| 09:45 ET | 1528 | 29.185 |
| 09:48 ET | 4298 | 29.15 |
| 09:50 ET | 1510 | 29.145 |
| 09:52 ET | 7469 | 29.17 |
| 09:54 ET | 6009 | 29.095 |
| 09:56 ET | 542 | 29.1 |
| 09:57 ET | 200 | 29.17 |
| 09:59 ET | 400 | 29.265 |
| 10:01 ET | 400 | 29.2 |
| 10:03 ET | 2100 | 29.24 |
| 10:08 ET | 100 | 29.12 |
| 10:10 ET | 1034 | 29.2 |
| 10:12 ET | 400 | 29.18 |
| 10:14 ET | 200 | 29.25 |
| 10:15 ET | 100 | 29.18 |
| 10:21 ET | 200 | 29.17 |
| 10:26 ET | 600 | 29.185 |
| 10:28 ET | 500 | 29.29 |
| 10:30 ET | 100 | 29.26 |
| 10:32 ET | 227 | 29.29 |
| 10:33 ET | 300 | 29.28 |
| 10:35 ET | 2641 | 29.27 |
| 10:39 ET | 200 | 29.34 |
| 10:42 ET | 500 | 29.19 |
| 10:44 ET | 800 | 29.22 |
| 10:46 ET | 200 | 29.225 |
| 10:48 ET | 100 | 29.25 |
| 10:51 ET | 100 | 29.28 |
| 10:53 ET | 100 | 29.27 |
| 10:55 ET | 700 | 29.325 |
| 10:57 ET | 700 | 29.35 |
| 11:02 ET | 200 | 29.34 |
| 11:04 ET | 100 | 29.32 |
| 11:06 ET | 100 | 29.33 |
| 11:09 ET | 200 | 29.32 |
| 11:11 ET | 200 | 29.32 |
| 11:13 ET | 8624 | 29.35 |
| 11:15 ET | 5820 | 29.255 |
| 11:18 ET | 700 | 29.31 |
| 11:20 ET | 2885 | 29.4 |
| 11:22 ET | 6204 | 29.47 |
| 11:24 ET | 300 | 29.495 |
| 11:26 ET | 339 | 29.495 |
| 11:27 ET | 800 | 29.49 |
| 11:29 ET | 2627 | 29.445 |
| 11:31 ET | 200 | 29.3 |
| 11:38 ET | 406 | 29.24 |
| 11:42 ET | 300 | 29.2 |
| 11:44 ET | 100 | 29.21 |
| 11:47 ET | 200 | 29.255 |
| 11:49 ET | 2801 | 29.34 |
| 11:51 ET | 11600 | 29.345 |
| 11:54 ET | 800 | 29.35 |
| 11:58 ET | 607 | 29.36 |
| 12:00 ET | 279 | 29.4 |
| 12:02 ET | 175 | 29.42 |
| 12:05 ET | 100 | 29.43 |
| 12:07 ET | 2427 | 29.4 |
| 12:09 ET | 2400 | 29.52 |
| 12:12 ET | 1200 | 29.54 |
| 12:14 ET | 11819 | 29.5 |
| 12:16 ET | 100 | 29.5 |
| 12:18 ET | 16123 | 29.57 |
| 12:20 ET | 600 | 29.615 |
| 12:21 ET | 100 | 29.64 |
| 12:23 ET | 200 | 29.66 |
| 12:25 ET | 700 | 29.74 |
| 12:27 ET | 1500 | 29.81 |
| 12:30 ET | 400 | 29.82 |
| 12:32 ET | 2513 | 29.88 |
| 12:34 ET | 400 | 29.885 |
| 12:36 ET | 1597 | 29.8 |
| 12:38 ET | 1635 | 29.84 |
| 12:39 ET | 500 | 29.89 |
| 12:41 ET | 100 | 29.825 |
| 12:43 ET | 300 | 29.63 |
| 12:48 ET | 100 | 29.59 |
| 12:50 ET | 634 | 29.595 |
| 12:52 ET | 419 | 29.59 |
| 12:54 ET | 100 | 29.56 |
| 12:56 ET | 200 | 29.55 |
| 12:59 ET | 200 | 29.59 |
| 01:01 ET | 505 | 29.615 |
| 01:03 ET | 527 | 29.65 |
| 01:06 ET | 346 | 29.605 |
| 01:08 ET | 100 | 29.58 |
| 01:12 ET | 15872 | 29.64 |
| 01:14 ET | 3377 | 29.72 |
| 01:15 ET | 200 | 29.715 |
| 01:17 ET | 500 | 29.66 |
| 01:19 ET | 500 | 29.62 |
| 01:21 ET | 300 | 29.6 |
| 01:24 ET | 300 | 29.59 |
| 01:26 ET | 200 | 29.565 |
| 01:28 ET | 814 | 29.6 |
| 01:30 ET | 400 | 29.625 |
| 01:32 ET | 300 | 29.62 |
| 01:33 ET | 400 | 29.57 |
| 01:35 ET | 581 | 29.55 |
| 01:37 ET | 200 | 29.54 |
| 01:42 ET | 100 | 29.5 |
| 01:44 ET | 500 | 29.55 |
| 01:46 ET | 770 | 29.595 |
| 01:48 ET | 100 | 29.57 |
| 01:50 ET | 100 | 29.615 |
| 01:53 ET | 676 | 29.61 |
| 01:55 ET | 300 | 29.58 |
| 02:00 ET | 700 | 29.64 |
| 02:04 ET | 898 | 29.605 |
| 02:08 ET | 100 | 29.61 |
| 02:11 ET | 100 | 29.54 |
| 02:13 ET | 500 | 29.555 |
| 02:15 ET | 100 | 29.53 |
| 02:20 ET | 100 | 29.53 |
| 02:22 ET | 965 | 29.56 |
| 02:26 ET | 100 | 29.59 |
| 02:27 ET | 300 | 29.62 |
| 02:29 ET | 1584 | 29.61 |
| 02:31 ET | 100 | 29.59 |
| 02:33 ET | 900 | 29.59 |
| 02:36 ET | 600 | 29.59 |
| 02:40 ET | 200 | 29.54 |
| 02:42 ET | 300 | 29.56 |
| 02:44 ET | 1000 | 29.615 |
| 02:47 ET | 900 | 29.68 |
| 02:49 ET | 500 | 29.68 |
| 02:51 ET | 2143 | 29.59 |
| 02:56 ET | 100 | 29.51 |
| 03:00 ET | 120 | 29.475 |
| 03:02 ET | 1400 | 29.49 |
| 03:03 ET | 200 | 29.46 |
| 03:05 ET | 1600 | 29.5 |
| 03:07 ET | 1100 | 29.55 |
| 03:09 ET | 1210 | 29.52 |
| 03:12 ET | 1200 | 29.5325 |
| 03:14 ET | 100 | 29.505 |
| 03:16 ET | 2007 | 29.55 |
| 03:18 ET | 794 | 29.55 |
| 03:20 ET | 643 | 29.53 |
| 03:21 ET | 8073 | 29.37 |
| 03:23 ET | 783 | 29.35 |
| 03:25 ET | 2175 | 29.42 |
| 03:27 ET | 700 | 29.46 |
| 03:30 ET | 400 | 29.46 |
| 03:32 ET | 1008 | 29.5 |
| 03:34 ET | 690 | 29.5 |
| 03:36 ET | 200 | 29.529 |
| 03:38 ET | 890 | 29.5 |
| 03:39 ET | 1704 | 29.52 |
| 03:41 ET | 1017 | 29.54 |
| 03:43 ET | 1078 | 29.525 |
| 03:45 ET | 3347 | 29.56 |
| 03:48 ET | 2700 | 29.59 |
| 03:50 ET | 2600 | 29.61 |
| 03:52 ET | 5468 | 29.555 |
| 03:54 ET | 4396 | 29.65 |
| 03:56 ET | 6971 | 29.56 |
| 03:57 ET | 9676 | 29.48 |
| 03:59 ET | 20865 | 29.43 |
Today
Apr 9, 2024
Agios Publishes 2024 Environmental, Social and Governance (ESG) Report, from 7:00AM ET on Tuesday Apr 09, 2024 by Dow Jones
7:00AM ET on Tuesday Apr 09, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Agios Pharmaceuticals Inc | 1.6B | -4.7x | --- |
Inhibrx Inc | 1.6B | -6.9x | --- |
Neumora Therapeutics Inc | 1.7B | -4.5x | --- |
Recursion Pharmaceuticals Inc | 1.8B | -4.7x | --- |
Structure Therapeutics Inc | 1.7B | -14.4x | --- |
Syndax Pharmaceuticals Inc | 1.8B | -6.9x | --- |
Company Information
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its genetically defined disease (GDD) portfolio, PYRUKYND (Mitapivat), is an activator of both wild-type and a variety of mutant pyruvate kinase (PK) enzymes, for the treatment of hemolytic anemias. The Mitapivat is an orally available small molecule and a potent activator of the pyruvate kinase R (PKR) enzymes. In addition, it is also evaluating mitapivat for the treatment of alpha- and beta- thalassemia and sickle cell disease (SCD) in ongoing clinical trials. The Company is also developing AG-946, a clinical-stage oral activator of PKR enzymes for the treatment of hemolytic anemias and other indications, including SCD.
Contact Information
- Headquarters
- 88 Sidney StreetCAMBRIDGE, MA, United States 02139
- Phone
- 617-649-8600
- Fax
- 302-655-5049
Executives
- Chairman of the Board
- Jacqualyn Fouse
- Chief Executive Officer, Director
- Brian Goff
- Chief Financial Officer
- Cecilia Jones
- Chief Legal Officer
- James Burns
- Head - Research and Development, Chief Medical Officer
- Sarah Gheuens
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.6B |
|---|---|
Revenue (TTM) | $26.8M |
Shares Outstanding | 56.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.84 |
EPS | $-6.33 |
Book Value | $14.50 |
P/E Ratio | -4.7x |
Price/Sales (TTM) | 60.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,459.52% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
